SCHEMBL4065461

SCHEMBL4065461

CC(=O)c1cn(CC(NS(=O)(=O)c2c(C)cc(C)cc2C)C(F)(F)F)c2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 13/20 0.70
NR3C2 P08235 13/20 0.70
PGR P06401 10/20 0.70
SMN1; SMN2 Q16637 5/20 0.48
LMNA P02545 3/20 0.48
HTT P42858 3/20 0.48
RAB9A P51151 2/20 0.48
POLB P06746 1/20 0.48
KAT2B Q92831 1/20 0.48
RXFP1 Q9HBX9 2/20 0.45
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
STAT3 P40763 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4417539 0.91 NR3C1 (0.69) NR3C1NR3C2PGRHTT
SCHEMBL4407287 0.90 NR3C1 (0.68) NR3C1NR3C2PGRLMNAPOLB
SCHEMBL4072559 0.88 NR3C1 (0.78) NR3C1NR3C2PGRCYP3A4
SCHEMBL4407316 0.84 NR3C1 (0.67) NR3C1NR3C2PGR
SCHEMBL4069137 0.83 NR3C1 (0.71) NR3C1NR3C2PGRSMN1; SMN2LMNA
SCHEMBL4071747 0.82 NR3C2 (1.00) NR3C1NR3C2PGRPOLBCYP3A4
SCHEMBL4407448 0.82 NR3C1 (0.64) NR3C1NR3C2PGRL3MBTL1
SCHEMBL4406095 0.82 NR3C1 (0.69) NR3C1NR3C2PGR
SCHEMBL4408014 0.81 NR3C1 (0.76) NR3C1NR3C2PGR
SCHEMBL13810671 0.81 KAT2B (0.47) NR3C1NR3C2PGRSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635711-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) 2009-12-22 US claimed
EP-1836166-B1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM PHARMA (US) 2009-06-17 EP claimed
EP-1836166-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2007-09-26 EP claimed
US-20060189646-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-08-24 US claimed
WO-2006071609-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-07-06 WO claimed
US-7635711-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-7635711-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-7635711-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER-INGELHEIM PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
EP-1836166-B1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM PHARMA (US) 2009-06-17 EP disclosed
EP-1836166-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2007-09-26 EP disclosed
US-20060189646-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-08-24 US disclosed
WO-2006071609-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189646-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof NR3C1, NR3C2, MC2R NR3C1 1/4885NR3C2 2/4885PGR 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.